Affiliation: | 1.Escola de Enfermagem Departamento de Enfermagem Materno-Infantil e Saúde Pública,Universidade Federal de Minas Gerais,Belo Horizonte,Brazil;2.Departamentos de Farmacologia, Instituto de Ciências Biológicas,Universidade Federal de Minas Gerais,Belo Horizonte,Brazil |
Abstract: | IntroductionThe aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on the healing of chronic foot ulcers in neuropathic patients with diabetes 2.MethodsFifty patients were enrolled in a prospective, randomized, double-blind trial, to verify the efficacy and safety of a topical dressing formulated with 0.1% P1G10, intended for wound healing, versus a hydrogel (control) protocol. Upon completion of the intervention, the outcome evaluated the number of patients attaining full epithelization (100%), or at least 80% healing. Statistical analysis compared the data on each group for the significance of the differences.ResultsCollection of data was finished in week 16, and the results were analyzed by intention to treat. The results showed that, in the control group, 5 patients attained 100% ulcer healing, 3 patients?≥?80% healing and 11 experienced ulcer changes?≤?80%, and the remainder showed no changes or their wounds became worse. Meanwhile, in the P1G10 group, 11 patients experienced full healing, 4 had healing?≥?80% and 5 had ulcer changes?≤?lower than 80%, and the remainder showed no changes or their wounds became worse. The healing incidence for the first endpoint (100% healing) showed that the P1G10 group was 2.95-fold more efficacious than the control group (CI 95%) and 2.52-fold (CI, 95%) higher than its control for the second endpoint (80% healing).ConclusionsThese data support the hypothesis that topical application of the proteolytic fraction identified as P1G10 significantly enhances foot ulcer healing compared to hydrogel treatment. |